1. ALLA AKTIER
  2. NYHETER
  3. XBRANE BIOPHARMA

Xbrane Biopharma

Nyheter Xbrane Biopharma Nyheter alla bolag

Xbrane Biopharma Completes Sale of XB003 and Parts of Its Organization to Alvotech

MARKN.

Xbrane Biopharma AB (publ) ("Xbrane" or the "Company") announced today that the transaction with Alvotech hf and its subsidiary Alvotech Sweden AB (jointly "Alvotech") regarding the sale of the biosimilar candidate XB003 (Cimzia) as well as parts of its organization has been completed, and that all regulatory conditions have been fulfilled.

The transaction, which was announced on March 20, 2025, and approved by the Extraordinary General Meeting on April 14, 2025, entails a total purchase price of approximately SEK 275 million, consisting of:

  • A cash payment of approximately SEK 102.2 million
  • Assumption of convertible debt from CVI Investments of approximately SEK 152.75 million
  • Assumption of XB003-related accounts payable of approximately SEK 20 million

"By completing this transaction, we significantly strengthen our financial position and can now fully focus on realizing the potential of our remaining programs, particularly Ximluci and Xdivane. We look forward to continuing our work in biosimilar development and creating value for our shareholders and patients," said Martin Åmark, CEO of Xbrane Biopharma.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 26 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com  

Attachments

Xbrane Biopharma Completes Sale of XB003 and Parts of Its Organization to Alvotech

Datum 2025-06-04, kl 13:45
Källa MFN
Bifogade filer
Xbrane Biopharma Completes Sale of XB003 and Parts of Its Organization to Alvotech
Affiliate
Skapa konto direkt med BankID hos Skilling så får du tillgång till tusentals finansmarknader inom valuta, aktier, krypto och mycket mer. Välj bland 1200+ CFD-instrument över 7 tillgångsklasser till konkurrenskraftiga priser. Skilling erbjuder också en kapitalförsäkring.
CFD är komplexa instrument och har en hög risk att förlora pengar snabbt på grund av hävstång. 77% av icke-professionella kunder förlorar pengar när de handlar med CFD med denna leverantör.